Paroxysmal Cold Hemoglobinuria Treatments
Find Paroxysmal Cold Hemoglobinuria Treatments
Medications for Paroxysmal Cold Hemoglobinuria
These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Paroxysmal Cold Hemoglobinuria.
Found 4 Approved Drugs for Paroxysmal Cold Hemoglobinuria
Eculizumab
Brand Names
BKEMV, Epysqli, Soliris
Eculizumab
Brand Names
BKEMV, Epysqli, Soliris
Form: Injection
Method of administration: Intravenous
FDA approval date: April 02, 2007
Classification: Complement Inhibitor
BKEMV is a complement inhibitor indicated for: The treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis.
Ultomiris
Generic Name
Ravulizumab
Ultomiris
Generic Name
Ravulizumab
Form: Solution
Method of administration: Intravenous
FDA approval date: December 21, 2018
Classification: Complement Inhibitor
ULTOMIRIS is a complement inhibitor indicated for: the treatment of adult and pediatric patients one month of age and older with paroxysmal nocturnal hemoglobinuria (PNH).
Voydeya
Generic Name
Danicopan
Voydeya
Generic Name
Danicopan
Form: Tablet, Kit
Method of administration: Oral
FDA approval date: March 29, 2024
Classification: Complement Factor D Inhibitor
VOYDEYA is indicated as add-on therapy to ravulizumab or eculizumab for the treatment of extravascular hemolysis (EVH) in adults with paroxysmal nocturnal hemoglobinuria (PNH). VOYDEYA is a complement factor D inhibitor indicated as add-on therapy to ravulizumab or eculizumab for the treatment of extravascular hemolysis (EVH) in adults with paroxysmal nocturnal hemoglobinuria (PNH) ( 1 ). Limitations of Use VOYDEYA has not been shown to be effective as monotherapy and should only be prescribed as an add-on to ravulizumab or eculizumab. Limitations of Use VOYDEYA has not been shown to be effective as monotherapy and should only be prescribed as an add-on to ravulizumab or eculizumab.
Piasky
Generic Name
Crovalimab
Piasky
Generic Name
Crovalimab
Form: Injection
Method of administration: Subcutaneous
FDA approval date: June 20, 2024
Classification: Complement C5 Inhibitor
PIASKY is indicated for the treatment of adult and pediatric patients 13 years and older with paroxysmal nocturnal hemoglobinuria (PNH) and body weight of at least 40 kg. PIASKY is a complement C5 inhibitor indicated for the treatment of adult and pediatric patients 13 years and older with paroxysmal nocturnal hemoglobinuria (PNH) and body weight of at least 40 kg ( 1 )
Showing 1-4 of 4
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances